CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
CHMP February 2026 Approvals: 12 New Medicines and Biosimilars Advance
The CHMP February 2026 approvals from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), held 23-26 February 2026, recommended marketing authorisation for 12 new medicines—including six biosimilars—plus six extensions of therapeutic indications and one positive opinion for use outside the EU. Key highlights include innovative therapies like the first combined influenza and COVID-19 mRNA vaccine (mCombriax) for adults aged 50 and older, addressing 281,728,062 reported COVID-19 cases in Europe as of 1 February 2026 and up to 50 million annual symptomatic influenza cases in the European Economic Area (EEA), as well as orphan-designated treatments like Ojemda (tovorafenib) for paediatric low-grade glioma. These recommendations, pending European Commission decisions, signal accelerated access to therapies for infectious diseases, rare conditions, and chronic disorders, tempered by two negative opinions and one application withdrawal.
Dual-Threat Vaccine and Orphan Brain Tumour Breakthroughs
Among the most impactful CHMP February 2026 approvals, mCombriax stands out as the inaugural combined messenger RNA (mRNA) vaccine targeting both seasonal influenza and COVID-19 in individuals aged 50 and older, supported by epidemiological data underscoring the dual disease burden. Ojemda received a conditional marketing authorisation for paediatric low-grade glioma in patients aged six months and older, offering a once-weekly oral alternative to surgery and chemotherapy, which often yields modest benefits with substantial side effects; its orphan designation highlights its role in addressing unmet needs in non-cancerous brain tumours. Similarly, Xolremdi (mavorixafor) earned a positive opinion under exceptional circumstances for WHIM (warts, hypogammaglobulinemia, infections, myelokathexis) syndrome from age 12, tackling a life-threatening ultra-rare immune deficiency prone to recurrent infections and viral-associated cancers. These approvals, alongside positives for Onerji in advanced Parkinson’s disease motor fluctuations, Palsonify in acromegaly, and Rhapsido in chronic spontaneous urticaria (CSU), exemplify CHMP’s prioritization of novel mechanisms for prevalent and orphan diseases, with six biosimilars—Bysumlog, Dazparda, Fubelv, Poherdy, Tuyory, and Zandoriah—poised to enhance affordability in diabetes, inflammatory arthritis, breast cancer, and osteoporosis management.
Accelerated Pathways and Rigorous Scrutiny
The CHMP’s evaluations draw on accelerated regulatory timetables for orphan medicines like Ojemda, Palsonify, and Xolremdi, and conditional authorisations that enable earlier access based on preliminary efficacy data amid ongoing studies. For instance, Acoziborole Winthrop benefited from the EU-Medicines for all (EU-M4All) procedure, facilitating a positive opinion for single-dose treatment of human African trypanosomiasis outside the EU to bolster global public health. Extensions of indications, such as Dupixent for paediatric CSU (ages 2-11) and Jorveza for eosinophilic oesophagitis (ages 2-17) in a child-specific formulation, address off-label use gaps, while negative opinions for Daybu in Rett syndrome and Iloperidone Vanda in schizophrenia/bipolar disorder reflect rigorous scrutiny of clinical evidence. This framework, detailed in pending question-and-answer documents and meeting minutes, ensures recommendations balance innovation with safety, as evidenced by the single withdrawal of Zumrad for bladder cancer.
Pricing Pressures and Reimbursement Shifts
Orphan designations for Ojemda, Palsonify, and Xolremdi may qualify them for market exclusivity incentives, potentially elevating negotiated prices despite conditional approvals, while necessitating real-world evidence generation to support sustained reimbursement amid modest chemotherapy comparators. Biosimilars like Fubelv (etanercept) and Tuyory (tocilizumab) promise cost savings in high-prevalence areas such as rheumatoid arthritis and COVID-19, aligning with trends toward biosimilar uptake to curb escalating biologic expenditures. Vaccine mCombriax could streamline national immunisation programs, reducing dual-disease administrative burdens tied to epidemiological data. Overall, these developments urge payers to integrate paediatric extensions—like Dupixent and Jorveza—into reimbursement pathways, mitigating off-label risks while advancing equitable access in paediatrics and rare diseases, consistent with broader EU efforts to harmonise HTA for innovative medicines.
